Search clinical trials for: Neoadjuvant and adjuvant durvalumab

Total 9375 results

Gustave Roussy, Cancer Campus, Grand Paris
AstraZeneca

Recruiting

Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) (POP-DURVA)

Early Small (cT1N0) Triple Negative Breast Cancer

France
University Hospital, Essen

Recruiting

Phase-II Trial of Induction Chemotherapy and Chemoradiotherapy Plus/Minus Durvalumab and Consolidation Immunotherapy in Patients With Resectable Stage III NSCLC. (ESPADURVA)

NSCLC, Stage III

Germany
Canadian Cancer Trials Group
AstraZeneca

Active, not recruiting

Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

Bladder Cancer

Canada, Spain, United Kingdom
AstraZeneca

Completed

Study to Access Safety of Durvalumab in Indian Adult Patients With Locally Advanced NSCLC

Unresectable Non-small Cell Lung Cancer (NSCLC)

India
IRCCS Policlinico S. Matteo

Active, not recruiting

Radiomic Signature as Predictive Marker of Response to Chemoradiation and Durvalumab in Stage III NSCLC.

Lung Cancer | Lung Cancer Stage III

Italy
Mario Negri Institute for Pharmacological Research

Completed

Diadem to Investigate the Activity and Safety of Durvalumab (Diadem)

Pleura Mesothelioma

Italy
Centre Hospitalier Universitaire Vaudois

Completed

Immunotherapy of Melanoma Patients

Melanoma

Switzerland
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)

Completed

Vaccine Therapy, Incomplete Freund's Adjuvant, and GM-CSF in Treating Patients With HIV

Nonneoplastic Condition

United States
Sun Yat-sen University

Recruiting

Hepatic Artery Infusion Chemotherapy (HAIC) Plus Durvalumab for Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
University Medical Center Groningen

Not yet recruiting

Evaluating PD-1/PD-L1 in Locally Advanced Rectal Cancer by Quantitative Fluorescence Molecular Endoscopy (PREDICT)

Locally Advanced Rectal Carcinoma

Netherlands
The University of Texas Medical Branch, Galveston
National Cancer Institute (NCI)

Terminated

Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Small Intestine Cancer | Gallbladder Cancer | Extrahepatic Bile Duct Cancer

United States
Pediatric Brain Tumor Consortium
National Cancer Institute (NCI)

Terminated

Carmustine Implants and O(6)-Benzylguanine in Treating Children With Recurrent Malignant Glioma

Brain and Central Nervous System Tumors

United States
MabVax Therapeutics, Inc.

Completed

Trivalent Ganglioside Vaccine With Immunological Adjuvant or Immunological Adjuvant Alone in Metastatic Sarcoma Patients Who Are Rendered Disease Free

Sarcoma

United States
Radboud University Medical Center
AstraZeneca

Completed

Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer (Donan)

Non-small Cell Lung Cancer

Netherlands
UNICANCER
AstraZeneca

Recruiting

Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax (DURVALUNG)

Small Cell Lung Carcinoma

France
Asan Medical Center

Active, not recruiting

Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer

Metastatic Colorectal Cancer

Korea, Republic of
University Hospital Inselspital, Berne
Celgene

Withdrawn

Durvalumab in DLBCL After Autologous Transplant (IDA-D)

Lymphoma, Large B-Cell, Diffuse
Spanish Cooperative Group for the Treatment of...
AstraZeneca

Recruiting

Olaparib and Durvalumab (MEDI4736) in Patients With Metastatic Pancreatic Cancer and DNA Damage Repair Genes Alterations

Metastatic Pancreatic Cancer

Spain
Roswell Park Cancer Institute

Completed

Pemetrexed Disodium and Cisplatin in Treating Patients Who Are Undergoing Surgery for Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

Lung Cancer

United States
Hospital Vall d'Hebron

Recruiting

Liver Transplant Combined With Neoadjuvant Chemo-radiotherapy in the Treatment of Unresectable Hilar Cholangiocarcinoma. A Prospective Multicenter Study.

Unresectable Cholangiocarcinoma

Spain
Abramson Cancer Center of the University of Pennsylvania
National Cancer Institute (NCI)

Completed

Vaccine Therapy in Treating Patients Who Are Undergoing Surgery for Ductal Carcinoma In Situ of the Breast

Breast Cancer

United States
Eastern Hepatobiliary Surgery Hospital

Not yet recruiting

Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma With High Predict Risk of Lymph Node Metastasis

Intrahepatic Cholangiocarcinoma Recurrent
Clover Biopharmaceuticals AUS Pty Ltd

Completed

SCB-2019 as COVID-19 Vaccine

COVID-19

Australia
University of Southern California
National Cancer Institute (NCI)

Completed

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Intraocular Melanoma | Melanoma (Skin)

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Soy Isoflavones in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage I or Stage II Adenocarcinoma of the Prostate

Prostate Cancer

United States
Ankara Etlik City Hospital

Completed

The Impact of Neoadjuvant Chemotherapy on Survival Outcomes in Patients With Variant Histologies Bladder Cancer Who Underwent Radical Cystectomy

Bladder Cancer | Bladder Cancer Stage I | Bladder Cancer Stage II

Turkey
Barbara Ann Karmanos Cancer Institute
AstraZeneca

Withdrawn

Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer
Arbutus Biopharma Corporation

Recruiting

Study of Imdusiran (AB-729) in Combination With Intermittent Dosing of Durvalumab in Subjects With Chronic HBV Infection

Hepatitis B, Chronic

Hong Kong, Spain, Taiwan, Thailand, United Kingdom, Poland, Georgia, Romania
AstraZeneca
Parexel

Recruiting

BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants (PATAPSCO)

Non-Muscle- Invasive Bladder Cancer

United States
AstraZeneca

Recruiting

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE)

Non-small Cell Lung Cancer

Spain, Italy, France, Canada, Portugal, United States, Czechia, Germany, Sweden, Austria, Hungary
ETOP IBCSG Partners Foundation
Takeda

Recruiting

Brigatinib Post Definitive Chemo-radiotherapy in Patients With ALK-fusion Non-small Cell Lung Cancer (BOUNCE)

NSCLC, Stage III | ALK-rearrangement

France, Spain, Italy, Poland, United Kingdom
Seoul National University Hospital

Recruiting

AZD6738 Plus Durvalumab in Biliary Tract Cancer

Bile Duct Cancer | Chemotherapy Effect

Korea, Republic of
AstraZeneca

Completed

A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer (NSCLC)

United Kingdom, United States, Italy, Spain, France, Germany
AstraZeneca

Completed

A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors

Solid Tumors

United States, France
AstraZeneca

Suspended

Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC (SOUND)

Lung Cancer

China
AstraZeneca
Parexel; Iqvia Pty Ltd; Medidata Solutions; CISCRP

Active, not recruiting

Durvalumab Long-Term Safety and Efficacy Study (WAVE)

Solid Tumor

Spain, United Kingdom, United States, Canada, Czechia, Poland, Romania, Thailand, Vietnam, Belgium, France, Korea, Republic of, Brazil, Hungary, Japan, Russian Federation, Malaysia, Taiwan, Australia, Germany, Turkey, Ukraine, Nethe... and more
Se-Hoon Lee
AstraZeneca

Completed

Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects (SUKSES-N4)

Small Cell Lung Cancer

Korea, Republic of
MedImmune LLC

Completed

A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors

Cancer | Solid Tumors

United States, Spain
Shadia Jalal, MD
AstraZeneca; MedImmune LLC; Big Ten Cancer Research Consortium

Completed

A Study of Durvalumab (MEDI4736) in Esophageal Cancer

Esophageal Cancer

United States
AstraZeneca

Completed

RELEVANCE - RWE Study in Unresectable Non-Small Cell Lung Cancer (Stage III) in Canada (RELEVANCE)

Non-small Cell Lung Cancer

Canada
PrECOG, LLC.
AstraZeneca

Completed

Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma (PrE0505)

Mesothelioma | Pleural Mesothelioma

United States
Groupe Oncologie Radiotherapie Tete et Cou
UNICANCER; Center Eugene Marquis

Active, not recruiting

Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN (REWRITe)

HNSCC

France
Intergroupe Francophone de Cancerologie Thoracique

Terminated

Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer (IONESCO)

Carcinoma, Non-Small-Cell Lung

France
Spanish Lung Cancer Group

Completed

Durvalumab in Solid Tumors

Cancer | HIV

Spain
MedImmune LLC

Completed

A Phase 1/2 Study to Evaluate MEDI4736

Advanced Solid Tumors

United States, Germany, Italy, United Kingdom, Belgium, Canada, Korea, Republic of, Taiwan, France
AstraZeneca
PRA Health Sciences

Completed

Phase II Study of MEDI4736 Monotherapy in Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

Recurrent or Metastatic PD-L1-positive Squamous Cell Carcinoma of the Head and Neck

United States, Belgium, Canada, France, Spain, Korea, Republic of, Hungary, Malaysia, United Kingdom, Taiwan, Germany, Georgia, Israel, Czechia
Samsung Medical Center

Unknown

Adjuvant Durvalumab for Esophageal Cancer

Esophageal Cancer

Korea, Republic of
European Organisation for Research and Treatment...

Completed

Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma

Malignant Mesothelioma

Belgium, Italy, Netherlands, United Kingdom
Second Affiliated Hospital of Guangzhou Medical...

Recruiting

Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors

Sarcoma | Cervical Cancer | Breast Cancer | Head and Neck Cancer | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Lung Cancer | Pancreas Cancer | Liver Cancer | Ovary Cancer

China
Radboud University Medical Center
AstraZeneca

Completed

PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC (PINCH)

Head and Neck Cancer

Netherlands

Search clinical trials for: Neoadjuvant and adjuvant durvalumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Singapore

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations